Abstract: The present invention provides a method for the treatment of diseases by the decomposition of peroxynitrite, preferably decomposition to benign products, comprising the use of a complex which is a selected ligand structure providing a complexed metal such as Mn, Fe, Ni and V transition metals. The method of use, as well as novel pharmaceutical compositions therefor, are for the treatment of diseases advantageously affected by decomposition of peroxynitrite ed at a rate over the natural background rate of decay of peroxynitrite in humans suffering from the disease which comprises administration of an amount of a complex, in dosage unit form, which is effective for such acceleration of the decomposition of peroxynitrite .

Abstract: Improved synthesis of a macropolycycle, more particularly, of a cross-bridged tetraazamacrocycle.

Abstract: This invention discloses compounds, and pharmaceutically acceptable salts thereof, useful in therapeutically and/or prophylactically treating patients with an illness. Such illnesses include cancer, and secondary infections caused by Pneumocystis carinii and Toxoplasmosis gondii in immunocompromised patients. The compounds themselves, methods of making these compounds, and methods of using these compounds are all disclosed.

Abstract: A salt of an anionic complex of Ru(III) with an ammonium cation fof formula (I), where R1, R2 and R3, equal or different from each other, are selected from the group consisting of H, C1-C6 alkyl, linear or branched, saturated or unsaturated, C3-C7 cycloalkyl, phenyl and aryl; or NR1R2R3 is a 5-7-membered nitrogen-containing heterocycle, saturated or unsaturated, optionally containing one or more O, S and/or N atoms, said nitrogen atom being optionally substituted with a C1-C4 alkyl, aryl or benzyl residue; said nitrogen-containing heterocycle being optionally condensed with a benzo group and/or substituted with C1-C4 alkyl, C1-C4 alkoxyl, C1-C4 alkylthio, aryl or benzyl groups; where R4 and R5, equal or different from each other, are selected from the group consisting of H, C1-C6 alkyl, C3-C7 cycloalkyl, phenyl and aryl or R4 and R5 form, together with the S atom, a 4-7-membered heterocycle.

Abstract: A method of manufacturing an organic pigment including the steps of providing an organic pigment wet cake which includes at least an organic pigment and a solvent and drying the organic pigment wet cake while the wet cake is heated at a temperature higher than room temperature to prepare a powder of the organic pigment, wherein the organic pigment is present in the organic pigment wet cake in an amount of not greater than about 70% by weight.

Abstract: Disclosed are novel prodrugs represented by the following structural formula; Z is oxygen or sulfur; Y is, together with a hydroxy group, acyclovir or an analog of acyclovir; A is a substituted benzyl group with one or more protected hydroxy or protected amine groups in the ortho or para positions, relative to the phosphate ester, which can be converted in vivo to a hydroxy or amino group. Also disclosed is a method of treating a viral infection in an individual or animal. The method comprises administering to the individual or animal a therapeutically effective amount of a prodrug represented by structural formula shown above.

Abstract: A process for preparing an HMX product comprises the steps of: (a) providing a granule that comprises a plurality of alpha-HMX particles and which has internal void spaces; and (b) sorbing at least one second material into the void spaces in the granule. The second material can be sorbed into the granules by using a vacuum to draw a gas phase comprising the second material into the granule. Alternatively, the second material can be sorbed into the granules by dissolving or dispersing the second material in a liquid solvent, contacting the solvent with the granules, and evaporating the solvent, whereby the second material is sorbed into the granules. Various second materials can be used, such as energetic materials and fuels.

Abstract: The present invention relates to compounds which are effective as catalysts for dismutating superoxide and, more particularly, the manganese or iron complexes of substituted, unsaturated heterocyclic pentaazacyclopentadecane ligands which catalytically dismutate superoxide.

Abstract: Aza- and diazacyclohexane and -cyclooctane compounds of the following formula: Ar1—A—B—Ar2  (I) where Ar1, A, B and Ar2 have the meanings stated in the description have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.

Abstract: The invention relates to a triaza-cryptand of the general Formula I wherein a is selected from the group consisting of 0 and 1, b and c independently are selected from the group consisting of 0 and 1, with the proviso that not both of b and c are 0, d is selected from the group consisting of 1, 2 and 3, e and f independently are selected from the group consisting of 0 and 1, with the proviso that not both of e and f are 0, R1 and R2 are either hydrogen or form an alkyl(C1-C4) benzene ring or an alkoxy(C1C4) benzene ring together with C1 and C2, wherein C2 is the para position, R3 and R2 are either hydrogen or form an alkyl(C1-C4) benzene ring or an alkoxy(C1-C4) benzene ring together with C3 and C4, wherein C3 is the para position, R5 and R6 are either hydrogen or form a benzene ring or a naphtalene ring together with C5 and C6, R7 and R8 are either hydrogen or form an alkyl(C1-C4) benzene ring or an alkoxy(C1-C4) benzene ring together with C7 and C8, wherein C8 is the para position,

Abstract: 1,3 Diazines according to formula (I): and pharmaceutically acceptable salts thereof inhibit phosphorylation of platelet-derived growth factor receptor and thereby hinder abnormal cell growth and cell wandering. The compounds may be used to treat or prevent cell-proliferative disorders such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.

Abstract: Novel macrocyclic compounds are constructed to include a ring or ring system having two bridgehead atoms with a bridge extending between the bridgehead atoms. Located in at least the bridge are two or more nitrogenous moieties that are derivatized with chemical functional groups. The ring or ring systems can include further nitrogenous moieties, either as ring atoms or on pendant groups attached to the ring. These can also be derivatized with chemical functional groups. The totality of the chemical functional groups imparts certain conformational and other properties to the compounds. In accordance with certain embodiments of the invention, libraries of such compounds are prepared utilizing permutations and combinations of the chemical functional groups and the nitrogenous moieties to build complexity into the library.

Abstract: A non-aqueous, particle-forming, fused pyrrolocarbazole-containing composition is disclosed. Upon contact with an aqueous medium, the particle-forming composition spontaneously disperses into suspended particles, thereby forming a stable suspension that provides greatly improved bioavailability of orally administered fused pyrrolocarbazole compounds.

Abstract: Androgen synthesis inhibitors, as well as methods for the use of the same to reduce plasma levels of testosterone and/or dyhydrotestosterone, and to treat prostate cancer and benign prostatic hypertrophy, are disclosed.

Abstract: A staurosporine derivative with anti-cancer activity and anti-bacterial activity is produced by acidifying a solution containing staurosporine to isomerize staurosporine to its desired derivative, whereby the derivative is recovered from the acidified solution.

Abstract: Described is a decolorizable dye represented by the following formula (I): wherein R1 represents an alkyl, aryl or heterocyclic group; R2 and R3 independently each represents a hydrogen atom or has the same meaning as R1 or may be coupled together to form a ring; L1 and L2 independently each represents a methine group or a nitrogen atom; L3 and L4 independently each represents a methine group; Z represents an atomic group necessary for the formation of a 5- or 6-membered hetero ring; m stands for 0 or 1; Y represents an oxygen, sulfur, selenium or tellurium atom; A represents a hydrogen atom or a group eliminative by solution treatment; V stands for a monovalent group; p stands for 0, 1, 2 or 3, X represents a counterion, and n stands for a numeral of 0 or greater necessary for the neutralization of an electron charge in the molecule.

Abstract: Novel compounds are constructed to include a central aromatic, aliphatic, or heterocyclic ring system. Attached to the central ring system are two linear groups having nitrogenous moieties that are derivatized with chemical functional groups. The ring system can include further nitrogenous moieties, either as ring atoms or on pendant groups attached to the ring, that may also be derivatized with chemical functional groups. The totality of the chemical functional groups imparts certain conformational and other properties to the these compounds. In accordance with certain embodiments of the invention, libraries of such compounds are prepared utilizing permutations and combinations of the chemical functional groups and the nitrogenous moieties to build complexity into the libraries.

Abstract: Novel lactams, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds of Formula I below: are useful in vitro or in vivo for preventing or treating coagulation disorders.

Abstract: Liquid personal cleansing emulsion compositions which contain a moisturizing phase and an aqueous cleansing phase. The moisturizing phase comprises a nonpolar, soluble lipophilic skin moisturizing agent. The aqueous cleansing phase comprises a soluble, noncrystalline synthetic surfactant in the lamellar phase, a stabilizer and water. the liquid personal cleansing compositions here contain less than about 5% insoluble crystalline surfactant.

Abstract: Metalloporphyrin-metal complex conjugates are prepared by reacting a porphyrin-metal complex conjugate with a metal acetylacetoane in a solvent or solvent mixture at a temperature from room temperature to 150° C. in concentrations of 3-30% in the metalloporphyrin-metal complex conjugate.